title: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
authors.affiliation: Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK. tim.shaw@roche.com
authors.forename: T
authors.initials: T
authors.lastname: Shaw
authors.forename: J
authors.initials: J
authors.lastname: Quan
authors.forename: M C
authors.initials: MC
authors.lastname: Totoritis
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018501:Antirheumatic Agents; D000069283:Rituximab